IN THE UNITED STATES PATENT AND TRADEMARK OFFICER 160

In re Application of:

R. MATALON et al.

erial No.: 09/965,807

Group Art Unit: 1653

Filed: October 1, 2001

Examiner: G. Bugaisky

For: APARTOACYLASE GENE, PROTEIN, AND METHODS OF SCREENING FOR MUTATIONS ASSOCIATED WITH CANAVAN DISEASE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

 \boxtimes

CITED MATERIALS

Appl	icant(s)	hereby	disclose	the in	formation	listed in	the attac	hed :	form l	PTC)- 1	449	€.
------	----------	--------	----------	--------	-----------	-----------	-----------	-------	--------	-----	-------------	-----	----

No. <u>08/128,020;</u> see 3 / C.F.R. § 1.98(d).
Copies of materials listed but not attached were cited in an International Search Report dated; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed

Copies of materials listed but not attached were cited in parent application Serial

ADDITIONAL INFORMATION

All lis	ted materials are i	in the English lan	iguage; see 3	7 C.F.R. § 1	.98.
Other					
comm	The reference recial search servi	rence(s) in the E	-	_ , ,	
□ knowi	No translation or n; an English-lang	r English-languag uage abstract the	· •		reference(s) is
-	office translated erpart foreign appl	_	pertinent p	art in conn	ection with a

<u>FEES</u>

\boxtimes	No fee is required for this Information Disclosure Statement because:
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
	☐ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
	☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
	A fee is required for this Information Disclosure Statement:
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
	This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.
CERT	<u>IFICATION</u>
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

2 SHUTT 1-C1

DEPOSIT ACCOUNT

If appropriate, attached is a check in the amount of \$\sum_\$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Nancy J. Axelrod

Registration No. 44,014

Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400

Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Date: December 18, 2001

Please type a plus si	gn (+) inside this	\rightarrow	+
-----------------------	--------------------	---------------	---

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

	Complete if Known	
Application Number	09/965,807	
Filing Date	October 1, 2001	
First Named Inventor	Matalon et al.	
Group Art Unit	1653	
Examiner Name	TBA	
Attorney Docket Number	SHUTT 1-C1	

					U.S. PATENT DOCUI	MENTS	
	Examiner Into s	Cite No.1	U.S. Pa	kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
0/1/2	*/						
\vdash							
F							
			<u> </u>				
H							
-			-				
	_						
L							

				FOREIG	N PATENT DOCU	IMENTS		
Examiner Initials*	Cite	For	eign Patent D	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
	No.1	Office ³	Number⁴	Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
-		-						
							-	
		1						
						1		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

KECEIVED

DEC 2 1 2001

Please type a plus sign (+) inside this box -> +

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ute for form 1449A/I	РТО			Complete if Known	
INIT		N DIO		Application Number	09/965,807	
			CLOSURE	Filing Date	October 1, 2001	
SIA	ILEMENI	BY A	PPLICANT	First Named Inventor	Matalon et al.	
				Group Art Unit	1653	
	(use as many	sheets as	necessary)	Examiner Name	TBA	-
Sheet	2	of	2	Attorney Docket Number	SHUTT 1-C1	

	, <u>.</u>	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner nitials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FFICE		Leong et al., Methods in Enzymology, 78: 87-101 (1981)	
THY OFFICE		Kaul et al., J. Neurochem. 56 (1) 129-135 (1991)	
		Matalon et al., Am. J. Med. Genet. 29: 463-471 (1988)	
		Adamo et al., J. Neurochem. 28 (4) 739-44 (1977)	
		Hagenfeldt et al., J. Inherit.Metab. Dis. 10 (2) 135-141 (1987)	
			ļ

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE VCZ

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.